ArGEN-X advances anti c-Met antibody

Thursday 9 February 2012

Venture-capital backed ArGEN-X BV of the Netherlands said that it has advanced a third therapeutic antibody candidate into preclinical development, in this instance an antibody targeting the c-Met signalling pathway which is implicated in many cancers.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Netherlands